US › Healthcare

Cytosorbents Crp (CTSO)

US · Healthcare · Medical Devices

$0.38+2.53%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$8.9M

Revenue YoY

+1.6%

Net profit

$-5.1M

Profit YoY

-246.9%

EPS

$-0.08

EPS estimate

$-0.05

Net margin

-57.9%

EPS came in at -0.08 against a street estimate of -0.05 — a miss of 60.0%.

Key statistics

Market cap

$22.7M

Forward P/E

7.2

P/B

10.47

Book value

$0.04

EPS (TTM)

$-0.19

52-week high

$1.22

52-week low

$0.35

50-day MA

$0.42

200-day MA

$0.62

Beta

1.39

Analyst view

Analysts rate Cytosorbents Crp a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $2.88.

Shareholding

Insiders

15.72%

Institutions

25.60%

Largest institutional holders

Fund	Stake
Avenir Corporation	8.30%
Vanguard Capital Management, LLC	2.99%
Neuberger Berman Group LLC	2.68%
CM Management, LLC	2.35%
Skylands Capital, LLC	1.93%
BlackRock Inc	1.25%
Geode Capital Management, LLC	1.13%
Sargent Investment Group, LLC	0.88%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cytosorbents Crp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.